key: cord-0932760-aq9n968i
authors: Huang, Yimin; Nguyen, Annalee W.; Hsieh, Ching-Lin; Silva, Rui; Olaluwoye, Oladimeji S.; Wilen, Rebecca E.; Kaoud, Tamer S.; Azouz, Laura R.; Qerqez, Ahlam N.; Le, Kevin C.; Bohanon, Amanda L.; DiVenere, Andrea M.; Liu, Yutong; Lee, Alison G.; Amengor, Dzifa; Shoemaker, Sophie R.; Costello, Shawn M.; Marqusee, Susan; Dalby, Kevin N.; D’Arcy, Sheena; McLellan, Jason S.; Maynard, Jennifer A.
title: Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses
date: 2021-08-20
journal: bioRxiv
DOI: 10.1101/2021.01.31.428824
sha: 81dc62531d8974b8190519b175ea0c6f6396dabc
doc_id: 932760
cord_uid: aq9n968i

Three pathogenic human coronaviruses have emerged within the last 20 years, with SARS-CoV-2 causing a global pandemic. Although therapeutic antibodies targeting the SARS-CoV-2 spike currently focus on the poorly conserved receptor-binding domain, targeting essential neutralizing epitopes on the more conserved S2 domain may provide broader protection. We report an antibody binding an epitope conserved in the pre-fusion core of MERS-CoV, SARS-CoV and SARS-CoV-2 spike S2 domains. Antibody 3A3 binds a conformational epitope with ~2.5 nM affinity and neutralizes spike from SARS-CoV, SARS-CoV-2 and variants of concern in in vitro pseudovirus assays. Hydrogen-deuterium exchange mass spectrometry identified residues 980-1006 in the flexible hinge region at the S2 apex as the 3A3 epitope, suggesting 3A3 prevents the S2 conformational rearrangements required for conversion to the spike post-fusion state and virus-host cell fusion. This work defines a conserved vulnerable site on the SARS-CoV-2 S2 domain and guides the design of pan-protective spike immunogens.

COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has 35

been responsible for over 4 million deaths worldwide since it was identified in late 2019. This pandemic is 36 the latest and largest of three deadly coronavirus outbreaks, including those caused by SARS-CoV in 2002 37

and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012. Although COVID-19 has a case 38

fatality rate estimated at ~1-3% versus ~10% for SARS-CoV and ~34% for MERS 1 , it has proven to be far 39 more infectious and its spread has impacted every aspect of society worldwide. Four other coronaviruses 40 are known to infect humans, resulting in relatively mild upper respiratory disease and symptoms: 229E, 41

OC43 (both discovered in the 1960s), NL63 (2004) , and HKU1 (2005) . All seven coronaviruses are 42 zoonotic, and many other coronaviruses are endemic in animals, foreshadowing future coronavirus 43

outbreaks. 44

Coronaviruses are enveloped positive sense, single-stranded RNA viruses that invade target cells by fusion 45

of the viral envelope with the target cell membrane, mediated by the spike glycoprotein. The spike is a 46

homo-trimer comprised of S1 and S2 domains: S2 forms a stalk-like structure proximal to the viral envelope 47

while S1 forms a cap covering the S2 apex. Each S1 domain monomer contains an N-terminal domain 48

(NTD) and a receptor-binding domain (RBD) that overlaps adjacent NTDs and RBDs within the trimer, 49

forming a responsive surface that allows each RBD to extend to the "up" position for receptor binding or 50 tuck into the "down" position for immune shielding. When RBDs engage a receptor in the up position and 51

target-cell-anchored proteases prime the spike, the S1 domain is released from S2, propelling the fusion 52

peptide into the target cell surface. Simultaneously, S2 undergoes a massive structural rearrangement to 53

bring the viral envelope into contact with the target cell, initiating fusion and leaving spike in the post-54 fusion state 2 . 55

A powerful strategy to prevent coronavirus fusion is to disrupt the interaction between the RBD and its host 56 cell receptor. For SARS-CoV-2, the receptor is angiotensin-converting enzyme 2 (ACE2), and antibodies 57 that block RBD binding to ACE2 are both potently neutralizing and common in convalescent patient sera 3 . 58

Accordingly, most monoclonal antibody therapies in development target this interaction 4 . However, RBD 59 sequences from different coronaviruses vary considerably to allow for binding to different host cell 60 receptors. Even within the three human-relevant coronaviruses that bind ACE2 (SARS-CoV, SARS-CoV-61 2 and NL63), RBD-binding antibodies exhibit limited cross-reactivity 5 , consistent with the low level of S1 62 sequence conservation (~20-24% identity, ~41-52% similarity; Supplementary Fig. 1 ). As a result, it has 63 been difficult to identify antibodies binding multiple lineage B b-coronaviruses, such as SARS-CoV and 64 SARS-CoV-2 6 , much less to include the lineage C MERS-CoV. In the CoV-AbDab database 7 there are only 65 currently two antibodies reported to neutralize SARS-CoV, SARS-CoV-2 and MERS-CoV and neither bind 66 the S1 domain. 67

By contrast, S2 is the most conserved spike domain, with 63-98% sequence similarity in pairwise 68

comparisons across the seven human coronaviruses ( Supplementary Fig. 1) . Moreover, the functionally 69 analogous domain in the fusion proteins from influenza virus, respiratory syncytial virus (RSV) and human 70 immunodeficiency virus (HIV) contains potently neutralizing epitopes 8,9 , prompting speculation that the 71 spike S2 domain may also serve as an effective target for neutralizing antibodies. Multiple mechanisms of 72 spike fusion inhibition are being explored, including those that target the S2 domain to prevent S2 73 conformational rearrangement 10,11 , block the fusion peptide 12-14 , and interfere with S2 proteolytic 74 processing 15 . Strategies targeting the S2 domain aim to induce premature S1 shedding and non-productive 75 transformation into the post-fusion spike. Antibodies binding the S2 domain of SARS-CoV-2 or conserved 76 epitopes on S2 are critical to support these efforts, but few have been reported in detail. Structures of S2-77 binding antibodies are limited to two peptide-antibody complexes for antibodies that bind the membrane-78

proximal stem helix of the spike 10,11 . Of the over 2500 anti-SARS-CoV-2 spike antibodies reported in the 79

CoV-AbDab database, less than 3% are reported to bind both SARS-CoV and SARS-CoV-2 spike and less 80 than 10% bind the S2 region. A total of 13 reported S2 binding antibodies have neutralizing capacity 7 . 81

Here, we aimed to identify unique epitopes conserved across all known highly pathogenic coronaviruses. 82

To focus immune responses on the S2 domain, we immunized mice with a stabilized MERS-CoV S2 protein 83

and isolated antibodies using alternate rounds of selection with the MERS-CoV S2 and intact SARS-CoV-84 2 spike using phage display. Of three high affinity, cross-reactive antibodies characterized, 3A3 neutralizes 85 SARS-CoV-2 spike in cell fusion and pseudovirus assays by binding a conformational epitope at the apex 86 of the S2 domain. This epitope is available for 3A3 binding only when the spike protein is fully open or 87

splayed into three C-terminally tethered protomers in a recently described spike conformation 16 . The 3A3 88 epitope defines a novel conserved site of vulnerability, which is increasingly relevant for more transmissible 89 spike variants, future pan-coronavirus vaccine designs and other therapeutic strategies. 90

Three unique antibody families binding a broad range of spike variants were identified from a mouse 94 immune phage library. Balb/c mice were immunized with stabilized MERS-CoV S2 protein and boosted 95

four weeks later, resulting in robust serum antibody titers (detectable at >1:10,000 dilution). The MERS-96

CoV S2 protein includes amino acid residues 763-1291 of the MERS-CoV spike protein with a C-terminal 97 T4 phage fibritin (foldon) domain that assembles into a pre-fusion trimer. In this work, "spike" refers to the 98 extracellular coronavirus fusogen domains containing homologous 2P mutations (residues 986 and 987 17 in 99 SARS-CoV-2) C-terminally fused to a foldon domain, whereas "unstabilized" refers to spike variants as 100 expressed on the virion without stabilizing changes, with other variations noted. "Wild-type" SARS-CoV-101 2 spike refers to the spike sequence originally reported in January of 2020 for 19A (Wuhan-Hu-1) SARS-102

CoV-2. 103

To generate immune antibody libraries, total mRNA was isolated from the mouse spleens and reverse 104 transcribed; the antibody variable regions were then amplified 18 and inserted into the pMopac24 M13 105 bacteriophage display vector 19 to express scFv-c-myc tag-pIII fusion proteins. The phage display library 106 (~3.1×10 8 individual clones) was subjected to four rounds of panning with immobilized antigen: anti-c-107 myc antibody to deplete truncated non-expressing clones, then MERS-CoV S2, and finally SARS-CoV-2 108 spike at high followed by moderate coating concentrations. Phage clones isolated after rounds 3 and 4 were 109 confirmed to bind MERS-CoV S2 and SARS-CoV-2 spike by ELISA and evaluated for binding to uncoated 110 plates and the foldon domain. While no clones exhibited plate or milk binding, ~85% of round 3 and 4 111

clones bound the shared foldon domain fused to the RSV F protein 20 ( Supplementary Fig. 2 ). One of these 112 foldon binders, 3E11, was carried forward as a control antibody, while the remaining clones identified three 113 spike-specific families: 3A3, 4A5, and 4H2. Antibody 3A3 and close relatives appeared in round 3 and 114 were enriched to ~10% of the population after round 4, while 4A5 and 4H2 were unique sequences isolated 115 after round 4 of panning. 116

After expression in ExpiCHO cells and purification of 3A3, 4A5, 4H2, and 3E11 as full-length antibodies 118

with human IgG1 and kappa constant domains, the antibodies were biophysically characterized to measure 119 spike binding affinity by biolayer interferometry (BLI) and surface plasmon resonance (SPR), thermal 120 unfolding by thermal shift, polydispersity by size exclusion chromatography (SEC), and purity by SDS-121 PAGE (Table 1 and Supplementary Figs. 3 and 4) . The antibodies all appeared as expected for intact 122 immunoglobulins, with 4A5 exhibiting a slightly delayed SEC retention volume. All four antibodies 123 exhibited low-to mid-nanomolar equilibrium affinities for the SARS-CoV-2 spike 17 as measured by BLI. 124

Additional measurements with SARS-CoV-2 HexaPro, an ultra-stable SARS-CoV-2 spike variant with six 125

proline substitutions relative to wild-type spike 21 , confirmed these affinities. The binding of 3A3 Fab to the 126 isolated S2 domain of SARS-CoV-2 HexaPro revealed similar ~2.5 nM Kd values by both SPR and BLI. 127

The on-and off-rate constants for HexaPro S2 binding in the absence of S1 were ~2×10 6 M -1 s -1 and 5×10 -3 128 s -1 , respectively (Supplementary Fig. 4) . 129

To assess the phylogenetic range of spike recognition by these three antibodies, binding to SARS-CoV, 130

SARS-CoV-2, MERS-CoV, and HKU1 as well as SARS-CoV-2 HexaPro spikes, and RSV F-foldon control 131

was assessed by ELISA ( Fig. 1a and Supplementary Fig. 5 ) and validated with BLI Kd measurements (Table  132 1 and Supplementary Fig. 4d ). Antibodies 3A3, 4A5 and 4H2 retained strong binding to the SARS-CoV 133 spike, MERS-CoV spike and MERS-CoV S2 domain but exhibited significantly reduced binding to HKU1 134 spike and no detectable binding to RSV F-foldon. Specifically, 3A3 exhibited an affinity of 20 nM for 135 SARS-CoV and 23 nM for MERS-CoV intact spikes. The foldon binding antibody 3E11 showed relatively 136 high binding affinity ~3-11 nM across all spikes and the RSV F-foldon as expected since these proteins all 137

include foldon domains for stabilization. 138

To further investigate the basis for spike protein recognition, the SARS-CoV-2, SARS-CoV-2 HexaPro, 140

MERS-CoV, and HKU1 spikes were fully denatured and reduced and subjected to western blotting. 141

Quadruplicate blots were incubated with each full-length antibody and binding to the spike polypeptide was 142 detected with anti-human-Fc-HRP and chemiluminescent peroxidase substrate ( Fig. 1b and Supplementary 143 Fig. 5c ). Antibodies 4A5, 4H2, and 3E11 detected linearized SARS-CoV-2, SARS-CoV-2 HexaPro, and 144

MERS-CoV spike proteins, with undetectable binding to HKU1 spike. In contrast, 3A3 did not bind any 145 spike protein in western blot, indicating that the 3A3 antibody binds a conformational epitope, while the 146 other three antibodies recognize epitopes with significant linear components. 147

To better understand the 3A3 conformational epitope, we evaluated 3A3 binding to fresh versus stressed 148 SARS-CoV-2 spike by ELISA ( Fig. 1c and d, and Supplementary Fig. 5d ). Soluble SARS-CoV-2 spike is 149 sensitive to freeze-thaw stresses; by contrast, SARS-CoV-2 HexaPro includes four additional proline 150

substitutions and exhibits resistance to freeze-thaw stresses 21 . We stressed spike by three freeze/thaw 151 cycles, which produced SDS-PAGE-detectable aggregates in the SARS-CoV-2 spike but not SARS-CoV-152

2 HexaPro ( Supplementary Fig. 6 ) and captured spike on antibody-coated ELISA plates. Antibodies 4A5, 153

4H2, and 3E11 bound fresh and stressed SARS-CoV-2 spike proteins similarly, with 4A5 and 4H2 binding 154 stressed spike slightly better ( Supplementary Fig. 5d ). However, 3A3 bound stressed 2P spike with a ~150-155 fold worse EC50, while binding of stressed SARS-CoV-2 HexaPro was unaffected, indicating a reduced 156 capacity for 3A3 to bind misfolded and/or aggregated spike. 157

To investigate the ability of 3A3, 4A5, and 4H2 to impact spike function, we first employed a mammalian 159 cell fusion assay ( Fig. 2a and b , and Supplementary Fig. 7) . A CHO cell line expressing wild-type SARS-160

CoV-2 spike and GFP was incubated with ACE2-expressing HEK 293 cells dyed with the red fluorescent 161

Cell showed significantly reduced syncytia size in the presence of as little as 6.7 nM 3A3 (Fig. 2b) . 170

We next assessed 3A3 neutralization in an in vitro pseudovirus neutralization assay. Antibody neutralization, 3A3 bound unstabilized D614G spike displayed on mammalian cells more readily than wild-183 type spike by flow cytometry (Supplementary Fig. 9 ). 184

The neutralizing 3A3 epitope is located on the S2 hinge 185

To identify the specific epitope recognized by 3A3, we used hydrogen-deuterium exchange mass 186 spectrometry (HDX). We measured deuterium uptake of the SARS-CoV-2 HexaPro spike alone, as well as 187 bound by the 3A3 IgG or 3A3 Fab (Supplementary Tables 1 and 2 ). Complexes were formed with excess 188

antibodies such that the SARS-CoV-2 HexaPro spike was ~90% bound in both cases. We tracked 192 189 unmodified peptides through the deuteration time course (10 1 , 10 2 , 10 3 , and 10 4 s), and did not search for 190 glycosylated peptides as de-glycosylation had a small effect on 3A3 affinity (Table 1 and Supplementary 191 Fig. 10 ). Analysis of the raw deuterium uptake in the SARS-CoV-2 HexaPro spike alone is consistent with 192 a trimer during exchange; with relatively low deuterium uptake in the helix at the center of the trimer and 193

high deuterium uptake in the HR1 helix at the trimer's surface ( Supplementary Fig. 11 ). Further analysis of 194 the isotopic distribution width of peptides from regions of spike reported to display bimodality 16 is 195 consistent with the trimeric spike sampling an open conformation (Supplementary Table 3) . 196 Antibody epitopes were identified by examining the difference in deuterium uptake between SARS- 2 HexaPro spike in the free and antibody-bound states. We defined a significant difference in a change in 198 deuterium uptake greater than 0.2 Da with a p-value less than 0.01 ( Fig. 3a and b) . The binding of 3A3 IgG 199 caused a significant decrease in 12 peptides that redundantly span residues 980 to 1006 of the SARS-CoV-200

2 HexaPro spike ( Fig. 3c and Supplementary Fig. 12a ). These peptides have reduced deuterium uptake with 201 3A3 IgG at several timepoints during the exchange reaction. An identical result was obtained with the 3A3 202 Fab (Fig. 3b and c and Supplementary Fig. 12 ). In contrast to 3A3 IgG and Fab, similar experiments with 203 4A5 and 4H2 antibodies showed no significant difference in deuterium uptake upon antibody addition 204

( Supplementary Fig. 13 ). The epitopes recognized by 4A5 and 4H2 are distinct from 3A3 and possibly lie 205 in regions where we lack peptides. Taken altogether, these data show that the 3A3 epitope lies within 206

residues 980 to 1006 of the SARS-CoV-2 HexaPro spike. 207

Mapping the difference in deuterium uptake between free and 3A3-bound states onto the structure localizes 208 the epitope to the apex of the S2 domain, distal to the viral envelope ( Fig. 3d ). It covers the end of the HR1 209 helix, the two stabilizing proline mutations (residues 986 and 987) and the beginning of the CH helix. This 210 region is highly conserved in sequence and structure across all β-coronaviruses known to infect humans 211 (Fig. 4 , a and b), with Cα atoms RMSD ranging from 0.6 Å for HKU1 to 3.1 Å for MERS-CoV. Fourteen 212 of the solvent exposed residues within the epitope were altered to assess the impact on 3A3 binding. Three, 213

S982A (present in the B.1.1.7 SARS-CoV-2 Alpha variant), L984V and R995A improved 3A3 binding by 214 ELISA, while five (D985L, E988Q or I, D994A, L1001A and Q1002A) significantly reduced 3A3 binding 215 ( Fig. 4c and d, Supplementary Fig. 15 ). The most substantial impact was the near ablation of binding by 216 the substitutions at positions D985 and E988. These residues form a negatively charged patch adjacent to 217 the 2P changes, P986 and P987. Since E988Q is present in the spike proteins of the α-coronaviruses NL63 218

and 229E, these data suggest 3A3 neutralization may be limited to β-coronaviruses. In addition to the clear 219 role of residues near the S2 hinge, residues D994, L1001 and Q1002 lie deeper in the S2 core and are hidden 220

in prefusion trimer structures 17,21 , yet appear to contribute to 3A3 spike recognition. Substitutions that 221

improve binding are at the protomer interfaces and may destabilize the closed trimer conformation. 222

Confirming this epitope in MERS-CoV spike, 3A3 strongly bound MERS-CoV S2 but not a mutant with 223 the apex of the S2 domain replaced with a linker (Supplementary Figure 13) . 224

The epitope mapping and point mutagenesis data indicate that 3A3 binds near the trimer interface of S2, 226

which is poorly accessible in published spike ectodomain structures. Costello SARS-CoV-2 HexaPro spike that was locked into the closed conformation by engineered disulfide bonds 24 231 (Fig. 5a , bottom) although this constrained spike was recognized by the control 2-4 antibody that binds the 232

RBDs in the down state (Fig. 5a, top) . 233

Analysis of 3A3 binding to various SARS-CoV-2 and SARS-CoV-2 HexaPro spikes with identical 3A3 234 epitope sequences resulted in inconsistent on-rates and Kd values by BLI, likely reflecting epitope 235 accessibility as opposed to the affinity of the epitope/paratope interaction (Fig. 5b, Supplementary Fig. 16 ).

Preincubating spike at 4°C for over one week or 37°C for 24 hours biases spike into the S2-open versus S2-237 closed conformation, respectively, and correspondingly alters the fraction of spikes with accessible epitope 238 and the apparent 3A3 binding kinetics. The SARS-CoV-2 spike is slightly unstable at 37°C, which alters 239 association of the control antibody S309 22 for spike by ~2-fold (BLI data; Fig. 5b ) and EC50 by ~3-fold 240

(ELISA data; Supplementary Fig. 17 ) relative to spike incubated at 4°C. However, 3A3-SARS-CoV-2 spike 241

binding was markedly reduced after 37°C incubation (~5.5-fold reduced on-rate constant by BLI and ~30-242

fold increase in ELISA EC50). This was also evident in 3A3 binding to SARS-CoV-2 HexaPro after 4°C or 243

37°C incubation (Fig. 5b) . In general, SARS-CoV-2 spike had faster 3A3 on-rate kinetics than SARS-CoV-244

2 HexaPro, perhaps due to the bias toward the S2-open state in SARS-CoV-2 spike relative to SARS-CoV-245

2 HexaPro 16 ( Supplementary Fig. 17 ). 246

Two additional SARS-CoV-2 HexaPro variants were produced to confirm binding to the S2-open spike 247

state. The E1031R substitution was introduced into SARS-CoV-2 HexaPro, which is outside of the 3A3 248 epitope but disrupts an electrostatic interaction between E1031 and R1039 on adjacent protomers deep in 249 the S2 base. When evaluated by HDX, this substitution promoted the formation of the S2-open state relative 250

to unmodified HexaPro ( Supplementary Fig. 18a ). To generate a monomeric HexaPro (monoHP) in which 251 the 3A3 epitope is always exposed, a protease cleavage site was introduced between the C-terminus of the 252 SARS-CoV-2 HexaPro spike and the foldon domain. After 5 days of 4°C incubation, the foldon 253 trimerization motif was cleaved and monoHP isolated by SEC ( Supplementary Fig. 18b ). When either 254 E1031R or monoHP was assessed for 3A3 binding by BLI, the on-rate was faster than that of fresh, 4°C 255 stored, or 37°C stored unmodified SARS-CoV-2 HexaPro, likely due to improved epitope accessibility 256 (Fig. 5b) . cell fusion and pseudovirus neutralization assays (Fig. 2) , 3A3 primarily binds when the spike attaches to 261

ACE2. BLI was used to confirm that spike can simultaneously bind ACE2 and 3A3. Immobilized 3A3 262 captured SARS-CoV-2 HexaPro and then soluble ACE2 (Fig. 5c , right), while mAb 2-4, which binds the 263 RBD down state across protomers, could bind SARS-CoV-2 HexaPro but the complex could not 264 simultaneously bind ACE2 (Fig. 5c, left) . 265

The regular emergence of pathogenic coronaviruses over the past two decades motivated our efforts to 267

isolate cross-reactive coronavirus spike antibodies. In all highly pathogenic coronaviruses, the spike protein 268

is responsible for targeting host cells via the S1 domain, which has little sequence similarity across 269 coronaviruses (41-87%; Supplementary Fig. 1 ). In contrast, the S2 domain mediates fusion of the viral 270 envelope and target cell membrane through a complex conformational change 2 , with a correspondingly low 271 tolerance for sequence variation (63-98% similarity; Supplementary Fig. 1) . Moreover, neutralizing sera 272 from individuals never exposed to SARS-CoV-2 is common in young people and exclusively bind the S2 273 domain 25 . Accordingly, S2 is an attractive target for pan-coronavirus antibody therapy and vaccination.

With this in mind, we isolated and characterized 3A3, a neutralizing and highly cross-reactive antibody 275

binding S2 from a MERS-CoV S2 immune phage library. 276 Antibody 3A3 binds a highly conserved conformational epitope near the S2 hinge and binds the isolated 277 SARS-CoV-2 HexaPro S2 domain with a low-nanomolar Kd by SPR (Table 1 and Supplementary Fig. 4) .

It exhibits similar binding to the full ectodomain of SARS-CoV-2 HexaPro, SARS-CoV, SARS-CoV-2, 279

and MERS-CoV spikes in ELISA and BLI assays (Kd values between 2.5 and 23 nM; Fig. 1 , Table 1 and 280

Supplementary Figs. 4 and 5), with minimal binding to the less pathogenic HKU1 spike (Fig. 1a) . In 281 addition, 3A3 neutralizes SARS-CoV and SARS-CoV-2 spikes in multiple in vitro assays (Fig. 2) , with 282

greater potency for the more transmissible D614G and B.1.1.7 variants. The 3A3 binding site was identified 283

by HDX as a cryptic epitope at the apex of S2 (residues 986-1006; Fig. 3 ). This epitope is conformational, 284

as 3A3 is unable to bind spike stressed by heat and freeze-thaw treatments (Fig. 1) . Mutational analysis 285

identified two hot spot residues (D985 and E988) which flank the 2P stabilizing mutations at the "jackknife 286

hinge" between HR1 and the central helix ( Fig. 4b-e ). This hairpin converts into a long, straight helix 287 during viral fusion, suggesting that 3A3 neutralizes by preventing hairpin extension. 288

Recent work revealed that 3A3 can only bind SARS-CoV-2 spike when S2 opens to expose the trimer 289

interfaces 16 , suggesting this state is required for 3A3 protection in neutralization assays. Analysis of spike 290

pre-fusion structures shows the 3A3 epitope to be completely obscured when the RBDs are in the three-291 down or "closed" conformation but is partially exposed when the RBDs become uncoupled from 292

neighboring NTDs 17,21 and fully exposed when S2 opens 16 . Our biochemical data show that 3A3 does not 293

bind spike locked in the closed, three RBD "down" state ( Fig. 5a ) but more rapidly associates with multiple 294 SARS-CoV-2 HexaPro variants having exposed S2 interfaces or when spike is treated to favor the S2-open 295 state (Fig. 5b ). D614G and B.1.1.7 pseudotyped virus are more readily neutralized by 3A3 than SARS-296

CoV-2 spike pseudovirus, suggesting that the S2-open versus S2-closed ratio and epitope accessibility are 297 altered in these more infectious variants 26,27 (Fig. 2c) . Conversely, 3A3 only weakly binds the HKU1 spike, 298

which contains three non-conservative changes within the 3A3 epitope (Fig. 4a) . None of these seem critical 299

for 3A3 binding (Fig. 4c) , suggesting the loss of binding is due to reduced epitope accessibility. For SARS-300

CoV-2 HexaPro spike, ACE2 binding biases the spike towards the S2-open state 16 , allowing 3A3 to bind 301 the ACE2-spike complex (Fig. 5c) , and suggesting that ACE2 engagement may expose the 3A3 epitope in 302 all variants. 303

Despite success in identifying neutralizing S1 epitopes on SARS-CoV-2 that block ACE2 interactions 6,28-304 33 , even broadly neutralizing RBD antibodies may be susceptible to escape 34-36 which has motivated interest 305

in the more conserved S2 domain. Over 200 S2 targeting antibodies have been reported 7 , but very few have 306 been described in detail. Chi et al. described over twenty SARS-CoV-2 S2 antibodies, several of which are 307 neutralizing but do not discuss their cross-reactive binding, epitopes, or mechanisms of neutralization 37 . In 308 other work, anti-SARS-CoV-2 S2 antibodies were reported that cross-react with SARS-CoV, MERS-CoV, 309

HKU1 and/or OC43 spike proteins 38 . One antibody binding all except OC43 neutralizes SARS-CoV and 310

SARS-CoV-2 pseudovirus by recognizing an epitope near the S2 base, opposite the 3A3 apex epitope. 311

Additional neutralizing antibodies binding spikes from the three highly pathogenic coronaviruses were 312

reported that bind similar regions on the S2 base 10,11 . By contrast, antibody 3A3, which was elicited by 313 mouse immunization with MERS-CoV S2 and selected with SARS-CoV-2 spike, is highly cross-reactive 314

with the MERS-CoV and SARS-CoV spikes and identifies a novel neutralizing epitope. Interestingly, 315

elicitation of antibodies binding this epitope is not limited to immunization with designed immunogens. An 316 antibody repertoire profiling effort recovered Ab127 from a convalescent COVID-19 patientand used HDX 317

to determine that it protects peptides 980-1006 (overlapping the 3A3 epitope) and 1179-1186 and binds 318 isolated S2 with a 471 nM affinity. 31 While Ab127 did not neutralize, likely due to its poor affinity, this 319

suggests that the 3A3 epitope is immunogenic during infection. 320

Broadly neutralizing antibodies binding epitopes on the fusogen trimer interface, similar to 3A3, have been 321

reported recently for other viruses. Here we report an antibody binding a neutralizing S2 epitope that is conserved across all highly pathogenic 345 coronavirus strains. HDX mapping and epitope mutagenesis identified the epitope in the hinge at the S2 346 apex, suggesting 3A3 inhibits the pre-to post-fusion spike transition. The 3A3 antibody binds spike when 347 the S2 domain trimer opens, a state which exists in equilibrium with the S2-closed prefusion state in 348 stabilized spikes. Multiple deployed vaccines utilize versions of the 2P stabilized SARS-CoV-2 spike, and 349 antibodies binding 3A3-like epitopes in the S2 core may be elicited during immunization. The relevance of 350 these antibodies in both convalescent and immunized individuals and for future protection from novel 351 coronaviruses is important to understand. Accordingly, future work will focus on affinity maturation of 352 3A3 and high-resolution structural analysis to determine the precise antibody footprint and neutralizing 353 mechanism. 354 355

Soluble coronavirus spikes and spike variants were expressed and purified as previously described 17,21 . 

Three BALB/c mice were immunized subcutaneously with 5 μg pre-fusion stabilized MERS-CoV S2 and 374 20 μg of ODN1826 + 100 μl of 2X Sigma Adjuvant System (SAS; Sigma) containing monophosphoryl 375 lipid A and trehalose dimycolate in squalene oil. Four weeks later, the mice were boosted with the same 376 dose of the same mixture. Three weeks after boosting, the mice were sacrificed and spleens were collected 377

in RNALater (ThermoFisher). The University approved mouse protocols of Texas at Austin IACUC (AUP-378 2018-00092). 379

RNA was isolated from the aqueous phase of homogenized spleens mixed with 1-bromo-3-chloropropane 381

and purified with the PureLink RNA kit (Invitrogen) separately. The Superscript IV kit (Invitrogen) was 382 used to synthesize cDNA. The VH and VL sequences from each immunized mouse were amplified with 383 mouse-specific primers described by Krebber 

The E.coli containing the library were expanded in growth media (2×YT with 1% glucose, 200 μg/mL 392 ampicillin, 10 μg/mL tetracycline) at 37 °C to an OD600 of 0.5, then infected with 1 × 10 11 pfu/mL M13K07 393

helper phage (NEB) and induced with 1 mM isopropyl β-d-1-thiogalactopyranoside. After two hours of 394

shaking at room temperature, 12.5 μg/mL of kanamycin was added for phage expression overnight. Phage 395

were precipitated in 20% PEG-8000 in 2.5 M NaCl, titered by infection of XL1-Blue and plating, and used 396 for Round 1 panning. This process was repeated for each round of panning, starting from overnight growth 397 of the output phage from each round. 398

Four rounds of panning were used to isolate scFvs binding both MERS-CoV S2 and SARS-CoV-2 spike 399 using the following solutions coated on high binding plates: 2 μg/mL anti-c-myc tag antibody (Invitrogen) 400

to eliminate phage expressing no or truncated scFv (Round 1), 2 μg/mL MERS-CoV S2 (Round 2), 2 μg/mL 401 SARS-CoV-2 spike (Round 3), and 0.4 μg/mL SARS-CoV-2 spike (Round 4). In each round of panning, 402

the plates were blocked with 5% non-fat milk in phosphate-buffered saline (PBS) with 0.05% Tween-20 403

(PBS-T), and phage were preincubated with 5% non-fat milk in PBS-T for 30 minutes before incubation 404 on the plate for 1.5 hours at room temperature. After thorough washing with PBS-T, output phage was 405 eluted using 0.1 M HCl at pH 2.2, neutralized with ~1:20 2 M Tris base, and allowed to infect XL1-Blue 406 cells overnight amplification. 407

Random clones isolated after Round 3 and Round 4 of panning were sequenced and unique clones were 408 tested by monoclonal phage enzyme-linked immunosorbent assay (ELISA) on plates coated with SARS-409

CoV-2 spike or RSV F foldon at 2 μg/mL in PBS. Briefly, plates were coated overnight at 4°C, washed 410

with PBS-T, then blocked with PBS-T and 5% milk. Phage were allowed to bind for one hour at room 411 temperature, thoroughly washed with PBS-T, then incubated with 1:2000 anti-M13 pVIII-HRP (GE 412

Healthcare) in PBS-T 5% milk for another hour. After washing, the plate was developed with the TMB 413

Substrate Kit (Thermo Scientific), quenched with an equal volume of 1 M HCl and evaluated by absorbance 414

at 450 nm ( Supplementary Fig. 2) . 415

Full-length antibody versions of 3A3, 4A5, 4H2, and 3E11 were cloned as previously described 47 as mouse 417

variable region-human IgG1 constant region chimeras. Antibodies were expressed in ExpiCHO 418 (ThermoFisher Scientific) cells according to the high titer protocol provided and purified on a Protein A 419

HiTrap column (GE Healthcare) with the ACTA Pure FPLC system (GE Healthcare), and buffer exchanged 420 to PBS. Each purified antibody was analyzed by SDS-PAGE (3 μg antibody per well) under reducing and 421 non-reducing conditions ( Supplementary Fig. 3a ) and by analytical SEC on a Superdex S200 column (GE 422

Healthcare) (Supplementary Fig. 3b) . 423

Mouse Fab fragments of each sequence were generated by cloning the VH and VL regions upstream of heavy 424 chain constant regions with a HRV3C protease site in the hinge 46 and a mouse kappa chain, respectively. 425

After expression, protein A purified protein was digested with HRV3C protease, and the flow-through from 426 a protein A HiTrap column was collected. Excess HRV3C protease was removed by incubation with Ni 427

Sepharose 6Fast Flow beads (GE Healthcare). Fully murine antibodies were produced by cloning the VH 428 regions into a mouse IgG2 expression cassette in the pAbVec background, co-transfected with the 429 appropriate mouse IgK plasmid 48 , and purified as described above. 430

According to the kit instructions, the thermal unfolding temperatures of the chimeric antibodies (0.3 mg/mL) 431

were assessed in triplicate using the Protein Thermal Shift Dye Kit (ThermoFisher Scientific). Continuous 432 fluorescence measurements (λex = 580 nm, λem = 623 nm) were performed using a ThermoFisher ViiA 7 433

Real-Time PCR System, with a temperature ramp rate of 0.05°C/sec increasing from 25°C to 99°C 434 (Supplementary Fig. 3c and d) . 435 ELISAs were performed as described above throughout the work. For testing each antibody's specificity, 437

plates were coated with 1 μg/mL of purified spike proteins (SARS-CoV, SARS-CoV-2, SARS-CoV-2 438

HexaPro, MERS-CoV, HKU1, and RSV F foldon) in PBS. Duplicate serial dilutions of each full-length 439

antibody were allowed to bind each coat, and the secondary antibody solution was a 1:1200 dilution of 440 goat-anti-human IgG Fc-HRP (SouthernBiotech). ELISA curves were fit to a 4-parameter logistic curve 441 (Fig. 1a and Supplementary Fig. 5a and b) . 442

To stress the spike proteins, fresh aliquots of SARS-CoV-2 and SARS-CoV-2 HexaPro spikes were thawed 443 and split. One half of the aliquot was stressed by incubation at -20°C for 5 min, then 50°C for 2 min for a 444 total of three temperature cycles. The freshly thawed and stressed spikes were serially diluted and captured 445

on ELISA plates coated with each full-length antibody at 1 μg/mL or nothing (no coat). The ELISA was 446 carried out as above with 3% w/v BSA in place of milk in the diluent and blocking buffer and Strep-Tactin-447 HRP (IBA) as the secondary reagent ( Fig. 1c and d, and Supplementary Fig. 5d ). For each fresh and stressed 448 spike, 8 µg was analyzed by SDS-PAGE under non-reducing conditions ( Supplementary Fig. 6) . 449

Purified coronavirus spike proteins (SARS-CoV-2 HexaPro, SARS-CoV-2, MERS-CoV, and HKU1) were 451 reduced and boiled, and 50 ng of each was subjected to SDS-PAGE and transfer to PVDF membranes in 452

quadruplicate. After blocking with PBS-T with 5% milk, the membranes were probed with 0.2 μg/mL 3A3, 453

1 μg/mL 4A5, 1 μg/mL 4H2 or 0.2 μg/mL 3E11 for 1 hour at room temperature. After washing with PBST, 454 the membranes were incubated with 1:4000 goat anti-human IgG Fc-HRP for 45 minutes at room 455 temperature, then developed with the SuperSignal West Pico Chemiluminescent Substrate (Thermo 456

Scientific) and imaged ( Fig. 1b and Supplementary Fig. 5c ). 457

SPR was used to determine the binding kinetics and affinity of the 3A3 Fab and HexaPro S2 interaction. 459

An anti-StrepTagII Fab was covalently coupled to a CM5 sensor chip, which was then used to capture 460 purified HexaPro S2 by the c-terminal twin StrepTag to ∼80 response units (RU) in each cycle using a 461

Biacore X100 (GE Healthcare). The binding surface was regenerated between cycles using 0.1% SDS 462 followed by 10 mM Glycine at pH 2. The 3A3 Fab was serially diluted from 12.5 nM to 1.56 nM and 463

injected over the blank reference flow cell and then HexaPro S2-coated flow cell in HBS-P+ buffer. Buffer 464 was also injected through both flow cells as a reference. The data were double-reference subtracted and fit 465 to a 1:1 binding model using BIAevaluation software. 466

To determine the affinity of 3A3 Fab by BLI, anti-human IgG Fc (AHC) (ForteBio) sensors were coated 467

with the anti-foldon antibody identified in this work (3E11) at 10nM in the kinetics buffer (0.01% BSA and 468 0.002% Tween-20 in PBS) to a response of 0.6 nm. MAb-coated sensors were then incubated with HexaPro 469 S2 at 60 nM to a response of 0.6 nm. Association of 3A3 Fab was recorded for 5 minutes in kinetics buffer, 470

starting at 100 nM followed by 1:2 dilutions. The dissociation was recorded for 10 minutes in the kinetics 471

buffer. Kd values were obtained using a 1:1 global fit model using the Octet instrument software. 3A3 Fab 472 kinetics measurement was repeated once (Supplementary Fig. 4b and Table 1) . 473

To determine the apparent Kd values of IgGs, anti-Human IgG Fc sensors were loaded with mAbs in the 474 kinetics buffer at 10 nM to a response of 0.6 nm. Association curves were recorded for 5 minutes by 475

incubating the sensors in different concentrations of spike or spike S2 domains, starting from 100 nM and 476 serially diluted at 1:2. The dissociation step was recorded for 10 minutes in the kinetics buffer. Steady-state 477

Kd values were determined using the response values obtained after five minutes of association using the 478

Octet analysis software (Table 1 and Supplementary Figs. 4c and d) . To evaluate spikes incubated at 479 different temperatures, the spikes were stored for ~1-3 weeks at 4°C or 24 hours at 37°C, then diluted into 480 room temperature buffer immediately before measurements.

To compare 3A3 and mAb 2-4 binding to HexaPro and "Down" HexaPro, anti-Human IgG Fc sensors were 483 loaded with 3A3 or mAb 2-4 mAb in the kinetics buffer at 10 nM to a response of 0.6 nm. After a baseline 484 step, the sensors were incubated with either HexaPro or "Down" HexaPro, both at 60 nM for five minutes. 485

Dissociation step was recorded for 10 minutes in the kinetics buffer (Fig. 5a) . 486

To evaluate ACE2 binding to HexaPro captured by 3A3, Anti-Human Fc Sensors were used to pick up 3A3 487 (10 nM) to a response of 0.6 nm. Then mAb coated tips were dipped into wells containing HexaPro (50 488 nM) to a response of 0.6 nm and then dipped into wells containing ACE2 (50 nM), irrelevant murine mAb 489

(50 nM), or buffer. Association of mu3A3/irrelevant mAb was measured for 5 minutes and dissociation for 490 10 minutes. (Fig. 5c) . 491

Octet Red96 (ForteBio) instrument was used. Between every loading step, sensors were washed with 492 kinetics buffer for 30 seconds. Before use, sensors were hydrated in the kinetics buffer for 10 minutes. After 493 each assay, the sensors were regenerated using 10 mM Glycine, pH 1.5. 494

On day 0, the CHO-T cells (Acyte Biotech) were transfected with either pPyEGFP 49 , 1:4 pWT-SARS-496

CoV-2-spike:pPyEGFP, and 1:4 pD614G-SARS-CoV-2-spike:pPyEGFP using Lipofectamine 2000 (Life 497

Technologies), and media was replaced on day 1. On day 2 after transfection, HEK-293T-hACE2 cells 498

(BEI, NR-52511), which stably expresses human ACE2, were stained with 1 μM CellTrace Far Red dye 499 (Invitrogen, Ex/Em: 630/661 nm) in PBS for 20 minutes at room temperature, then quenched with DMEM 500

with 10% heat-inactivated FBS for 5 minutes, and resuspended in fresh media. CHO-T cells expressing 501 EGFP or EGFP and surface spike were preincubated with the antibody for one hour at 37°C, then mixed 502

with HEK-hACE2 cells at a ratio of 5:1 in 24-well plates with a coverslip on the bottom of each well. On 503 day 3, after 20 hours of coincubation, the coverslip with bound cells was washed once with PBS and fixed 504 with 4% paraformaldehyde for 20 min at room temperature, washed again, and mounted on slides with 505 DAPI-fluoromount-G (Southern Biotech). Images were collected with Zeiss LSM 710 confocal microscope 506

(Carl Zeiss, Inc) and processed using ImageJ software (http://rsbweb.nih.gov/ij) ( Fig. 2 and Supplementary 507 Fig. 7 ). 508

The cell fusion level was determined by two different statistical analysis methods. The first statistical 509

analysis was based on the percentage of HEK-ACE2 pixels (red) colocalizing with spike expressing CHO 510 pixels (green), which was determined by the following equation within the JACoP plugin for ImageJ 50 : 511 512

The colocalization percentage for each independent image was determined using the Manders' coefficient. 515

The second statistical analysis was based on the average HEK-ACE2 cell size after the coincubation with 516 CHO cells using the ImageJ software. The image of HEK-ACE2 (red fluorescence color at 633 nm 517 wavelength) was converted into 16-bit in greyscale and adjusted the threshold to highlight the cell structure. 518

The average cell size was automatically counted with the "Analyze Particles" tab with a size threshold (50-519 infinity) to exclude the background noise. The cell on the edge was excluded. The statistical significance 520 of either HEK-ACE2 colocalization percentage or average cell size between different conditions was 521 calculated with ANOVA using GraphPad Prism 7 (GraphPad Software). Values represent the mean and 522

standard deviation of at least 160 cells. Prism v9.0) (Fig. 2) . 559

On day 0, Expi-293 cells (ThermoFisher) were mock transfected or transfected with pWT-SARS-2-spike 561 or pD614G-SARS-2-spike described for pseudovirus assays above. On day 2, 30 nM full-length 3A3 or 562

CR3022 was added to ~5×10 5 transfected cells for 1 hour on ice. All cells were collected, washed with PBS 563

with 1% FBS, then incubated with 1:100 goat-anti-human Fc-AF647 for one hour on ice. Cells were washed 564 again, then scanned for AF647 (640 nm excitation, 670/30 bandpass emission) fluorescence on a BD 565

Fortessa flow cytometer and analyzed with FlowJo ( Supplementary Fig. 9 ). 566 567

Hydrogen-Deuterium Exchange Mass Spectrometry 568

Hydrogen-deuterium exchange was performed on 0.50 μM SARS-CoV-2 HexaPro spike protein alone 569

( Supplementary Fig. 11 ) or in the presence of 0.55 μM 3A3 IgG or Fab ( Fig. 3 and Supplementary Fig. 12) , Acid as the basic LC buffer. 581 MS data were acquired using positive ion mode and either HDMS or HDMS E . HDMS E mode was used to 582 collect both low (6 V) and high (ramping 22-44 V) energy fragmentation data for peptide identification in 583

water-only samples. HDMS mode was used to collect low energy ion data for all deuterated samples. All 584 samples were acquired in resolution mode. The capillary voltage was set to 2.8 kV for the sample sprayer. 585

Desolvation gas was set to 650 L/hour at 175°C. The source temperature was set to 80°C. Cone and 586 nebulizer gas were flowed at 90 L/hour and 6.5 bar, respectively. The sampling cone and source offset were 587 set to 30 V. Data were acquired at a scan time of 0.4 s with a range of 100-2000 m/z. A mass correction 588 was done using [Glu1]-fibrinopeptide B as a reference mass. 589

Water-only control samples were processed by Protein Lynx Global Server v.3.0.2 with a 'minimum 590 fragment ion matches per peptide' of 3 and allowing methionine oxidation. The low and elevated energy 591 thresholds were 250 and 50 counts, respectively, and the overall intensity threshold was 750 counts. The 592

resulting peptide lists were then used to search data from deuterated samples using DynamX v.3.0. Peptide 593 filters of 0.3 products per amino acid and 1 consecutive product were used. Spectra were manually assessed, 594 and figures were prepared using HD-eXplosion 52 and PyMOL 53 . The HDX data summary table 595

(Supplementary Table 1) and complete data table (Supplementary Table 2 ) are included. 596

The means ± SD were determined for all appropriate data. For the mammalian cell fusion experiments, 598

pseudovirus neutralization experiments and epitope variant analysis, a one-way analysis of variance 599

(ANOVA) with Tukey's simultaneous test with P values was used to determine statistical significance 600 between groups. Welch's t-test was used to determine the significance of deuterium uptake differences. less than 10 -2 in a Welch's t-test (hatched box). Black dots indicate peptides with a significant decrease in 642 deuterium uptake and their boundaries are labeled. c Deuterium uptake plots for peptides with a significant 643 decrease in deuterium uptake upon addition of 3A3 (see Supplementary Fig. 12 ). Traces are SARS-2 644

HexaPro spike alone (black), with 3A3 IgG (blue), and with 3A3 Fab (orange). Error bars are ±2σ from 3 645 or 4 technical replicates. Y-axis is 70% of max deuterium uptake assuming the N-terminal residue 646 undergoes complete back-exchange. Data have not been corrected for back-exchange. d Monomeric SARS-647

CoV-2 2P spike (PDB: 6VSB chain B) colored according to the difference in deuterium fractional uptake 648 between SARS-2 HexaPro spike alone and with 3A3 IgG at 10 2 s exchange. The figure was prepared using 649

DynamX per residue output without statistics and Pymol. Residues lacking coverage are indicated in grey.

Structural features are labeled, including the 2P mutations at residues 986 and 987 (shown as sticks). 651 of beta coronaviruses known to infect humans, including B.1.1.7 (Alpha) and the Beta, Gamma, Delta, 656

and Epsilon variants of concern (Other VOC). In a, identical residues are indicated by a dot and similar 657 residues are highlighted in grey. Residues conserved across all listed β-coronaviruses are in bold in the 658 SARS-CoV-2 epitope. Residues that lost binding to 3A3 when altered as shown in c are in teal highlight 659

and those whose disruption improved binding are orange. The location of the two proline mutations 660 introduced to 2P variants are shown below the alignment. In b, the structure of each epitope is displayed 661 as follows: SARS-2 (6VSB) -red, SARS-1 (6CRV, RMSD = 0.8 Å) -magenta, MERS-CoV (5X5C, 662 RMSD = 3.1 Å) -blue, HKU1 (5I08, RMSD = 0.5 Å) -teal, OC43 (6OHW, RMSD = 0.6 Å) -green. c 663

Single point mutants of HexaPro had increased or decreased binding to 3A3 relative to HexaPro, 664

indicating residues important for 3A3 binding. Each mutant was tested in duplicate in two to five 665 independent ELISA assays. Significance of the difference relative to unmutated HexaPro was determined 4 54 (red lines) bound both SARS-CoV-2 HexaPro (HexaPro, solid) and HexaPro locked into the "closed" 679 conformation (dashed). 3A3 (blue lines) was able to capture HexaPro (solid), but not "closed" HexaPro 680

(dashed). Vertical dashed lines indicate start of the dissociation phase. b Antibody 3A3 or S309 was 681 coupled to anti-Fc BLI sensors and allowed to bind monomeric HexaPro (monoHP), E1031R HexaPro 682 (E1031R), HexaPro, or SARS-CoV-2 S2P (SARS-2) spike protein at several concentrations. The proteins 683

were freshly thawed from -80 °C (fresh; purple circles), incubated at 4 °C for one day for SARS-2 or 1 684

week for HexaPro (4°C; blue circles), or incubated at 37 °C for 1 day (37 °C; red circles). The on-rate of 685 binding (kon)was calculated from measurements at seven concentrations in two independent experiments 686 and error is the range of these measurements. c Antibody 3A3 or 2-4 were coupled to anti-Fc BLI sensors 687 and allowed to capture HexaPro or nothing (buffer), then dipped into buffer (baseline), and finally dipped 688 into ACE2-Fc (ACE2) or nothing (buffer). In all cases, data were double-reference subtracted. 689 2.7 ± 0.3 3.2 ± 0.3 8 ± 3 7.9 ± 0.8 20 ± 2 23 ± 1.2 5.9 ± 0.6 4A5 17 ± 4 11.0 ± 0.1 4 ± 1 10 ± 2 4 ± 0.9 ND ND 4H2 29 ± 4 63 ± 7 5.8 ± 0.9 9 ± 2 20 ± 2 ND ND

5.5 ± 0.7 8 ± 4 3.5 ± 0.6 11 ± 2 5.7 ± 0.5 

Isotype control >5000 >5000 >5000 >5000 >5000

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, 701 and Influenza A Respiratory Viruses

Distinct conformational states of SARS-CoV-2 spike protein

Recognition of the SARS-CoV-2 receptor binding 706 domain by neutralizing antibodies

Fruitful Neutralizing Antibody Pipeline Brings 709

Hope To Defeat SARS-Cov-2

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

Broad and potent activity against SARS-like viruses by an engineered 714 human monoclonal antibody

CoV-AbDab: the coronavirus antibody 716 database

A stable trimeric influenza hemagglutinin stem as a broadly protective 718 immunogen

Tackling influenza with broadly neutralizing antibodies

A human antibody that broadly neutralizes betacoronaviruses protects against 722 SARS-CoV-2 by blocking the fusion machinery

Structural basis for broad coronavirus neutralization

Protective Effect of Intranasal Regimens Containing Peptidic Middle 726

East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion 729 inhibitor

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising 731 antibodies in COVID-19 patients

Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping

The SARS-CoV-2 spike reversibly samples an open-trimer conformation 736 exposing novel epitopes

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Reliable cloning of functional antibody variable domains from hybridomas and 740 spleen cell repertoires employing a reengineered phage display system

Isolation and expression of recombinant antibody fragments to the biological 743 warfare pathogen Brucella melitensis

Structure-based design of a fusion glycoprotein vaccine for respiratory 746 syncytial virus

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. 750

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Controlling the SARS-CoV-2 spike glycoprotein conformation

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Spike mutation D614G alters SARS-CoV-2 fitness

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1

Synthetic repertoires derived from convalescent COVID-19 patients enable 762 discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality

A noncompeting pair of human neutralizing antibodies block COVID-19 virus 765 binding to its receptor ACE2

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to 767 angiotensin converting enzyme 2 receptor

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in 770 nonhuman primates

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-772

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. 774

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different 776 classes of antibodies

Prospective mapping of viral mutations that escape antibodies used to treat 778 COVID-19

SARS-CoV-2 escape <em>in vitro</em> from a highly neutralizing COVID-19 780 convalescent plasma

A neutralizing human antibody binds to the N-terminal domain of the Spike protein 782 of SARS-CoV-2

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 784 and endemic coronavirus infection

Transient opening of trimeric prefusion RSV F proteins

Mechanism of membrane fusion induced by vesicular stomatitis virus G protein

The high-affinity immunoglobulin receptor FcgammaRI potentiates HIV-1 791 neutralization via antibodies against the gp41 N-heptad repeat

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad 794 Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity

A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain 797

Trimer Interface

Molecular-level analysis of the serum antibody repertoire in young adults before 799 and after seasonal influenza vaccination

Stabilized coronavirus spikes are resistant to conformational changes 801 induced by receptor recognition or proteolysis

Immunogenicity and structures of a rationally designed prefusion MERS-CoV 804 spike antigen

A cocktail of humanized anti-pertussis toxin antibodies limits disease in 806 murine and baboon models of whooping cough

Human cytomegalovirus-specific T cell receptor engineered for high affinity 809 and soluble expression using mammalian cell display

Identification of high affinity HER2 binding antibodies 812 using CHO Fab surface display

A guided tour into subcellular colocalization analysis in light 815 microscopy

Protocol and Reagents for Pseudotyping Lentiviral Particles

CoV-2 Spike Protein for Neutralization Assays

HD-eXplosion: Visualization of hydrogen-deuterium 819 exchange data as chiclet and volcano plots with statistical filtering

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is 823 Mediated by Avidity

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

General: The following reagent was contributed by David Veesler for distribution through BEI 828

Vector pcDNA3.1(-) containing the SARS-Related Coronavirus

NR-52420 55 . The following reagents were obtained through BEI Resources

Human Embryonic Kidney Cells (HEK-293T) Expressing Human Angiotensin-Converting

Enzyme 2, HEK-293T-hACE2 Cell Line

NR-52516, NR-52517, NR-51518, and NR-833 52519); and Vector pHAGE2 Containing the ZsGreen Gene

Data and materials availability: Data and antibody sequences will be submitted to the Submit data to 852the Immune Epitope Database and Analysis Resource (iedb.org) and the Coronavirus Immunotherapy 853Consortium (covic.lji.org). 854